Nanomedicine Market by Modality Treatments and Diagnostics Application Drug Delivery Diagnostic Imaging Vaccines Regenerative Medicine Implants and Others and Indication Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological Diseases and Others Global Opportunity Analysis and Industry Forecast 2017 2023

BUY CHAPTERS

Nanomedicine Market Size, Share, Competitive Landscape and Trend Analysis Report, by Modality, Application and Indication : Global Opportunity Analysis and Industry Forecast, 2021-2030

Code: ALLI-Auto-4R191

Report

November 2019

Pages:190

Allied Market Research

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Nanomedicine Market Statistics 2030

Nanomedicine Market Reserach Report

The global nanomedicine market size was valued at $171,695.33 million in 2020, and is projected to reach $393,046.52 million by 2030, registering a CAGR of 9.2% from 2021 to 2030. Nanomedicine is the branch of medicine that applies knowledge of nanotechnology for prevention and treatment of diseases. Nanomedicine involves use of nanoscale materials, such as biocompatible nanoparticles and nanorobots for diagnosis, delivery, sensing, or actuation purposes in a living organism.

Nanomaterials possess novel physicochemical properties that are different from conventional bulk chemical equivalents, owing to their small size. These properties greatly increase a set of opportunities in drug development. Physicochemical properties of the nano formulation, which can lead to alteration of pharmacokinetics such as absorption, distribution, elimination, and metabolism, has the potential for more easily crossing biological barriers, toxic properties, and their persistence in the environment and human body. Pharmaceutical manufacturing of nanomaterials involves two different approaches that include top-down and bottom-down. The top-down process involves breakdown of a bulk material into a smaller one or smaller pieces by mechanical or chemical energy. Conversely, the bottom-down process starts with atomic or molecular species allowing precursor particles to increase in size through chemical reaction.

Growth of the nanomedicine market is driven by emerging innovative technologies for drug delivery, advantages of nanomedicine in various healthcare applications, and growth in need for safe and cost-effective therapies.

Moreover, rise in R&D studies regarding nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector also contribute toward the growth of the market. However, the long approval process and risks associated with nanomedicines (environmental impact) are expected to hinder the market growth. Conversely, increase in out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are expected to offer lucrative opportunities for growth of the market.

Impact Of Covid-19 On Nanomedicine Market (Pre And Post Analysis)

Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans. Amidst the initial outbreak of COVID-19, the outlook for the nanomedicine industry has changed significantly. The COVID-19 pandemic led to significant increase in demand for nanomedicines for treatment of various diseases. Applications of nanomedicine offered new opportunities for development of novel products for prevention, diagnosis, and treatment of COVID-19 virus and other viral infections. COVID-19 management was done with the development of nano-based materials, that included disinfectants, personal protective equipment, diagnostic systems, and nanocarrier systems for treatments and vaccine development. This impacted the market with increase in demand for nanomedicines. Overall, the impact of COVID-19 on the nanomedicine market was recorded to be fairly positive. This was attributed to increase in demand for nanomedicines in the treatment of cancer like diseases. Moreover, market players have experienced rise in investments in materials and resources, owing to increase in research and development activities in nanomedicines in all regions.

The nanomedicine market is segmented on the basis of modality, application, indication, and region. On the basis of modality, the market is segmented into diagnostics and treatment. On the basis of application, it is segmented into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. On the basis of indication, it is segmented into clinical oncology, infectious diseases, clinical cardiology, orthopedics, neurology, urology, ophthalmology, immunology and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Modality Segment Review

By modality, the global nanomedicine market is classified into diagnostics and treatment. The treatment segment was the major contributor to the global market in 2020, and is anticipated to remain dominant during the forecast period, owing to technological advancements in nanomedicines, increase in adoption of nanomedicines, rise in incidence rates of chronic diseases, and increase in number of advanced & effective product launches.

Application Segment Review
By application, the global nanomedicine market is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others. The drug delivery segment was the major contributor to the global market in 2020, and is anticipated to remain dominant during the forecast period, owing to increase in prevalence of diseases such as cancer and COVID-19 virus and increase in awareness of nanomedicines applications.

Indication Segment Review

By indication, the global nanomedicine market is classified into clinical oncology, infectious diseases, clinical cardiology, orthopedics, neurology, urology, ophthalmology, immunology and others. The clinical oncology segment was the major contributor to the global market in 2020, and is anticipated to remain dominant during the forecast period, owing to surge in number of oncology diseases and increasing disposable income.

Region Segment Review

North America accounted for a major share of the global nanomedicine market share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to increase in number of lethal diseases, surge in demand for nanomedicines, availability of advanced healthcare facilities with trained medical professionals, rise in number of R&D activities along with large presence of key players, and surge in investments made by governments in the healthcare system. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period. Moreover, Japan and China are expected to grow at high CAGR in Asia-Pacific nanomedicine market majorly due to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced instruments, development of the R&D sector, rise in healthcare reforms, and technological advancements in the field of nanomedicines.

Key Benefits For Stakeholders
1.This report provides a detailed quantitative analysis of the current nanomedicine market trends and forecast estimations from 2021 to 2030, which assists to identify the prevailing market opportunities.
2.An in-depth nanomedicine market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
3.A comprehensive analysis of factors that drive and restrain the growth of the global nanomedicine market is provided.
4.The projections in this report are made by analyzing the current trends and future market potential from 2020 to 2030, in terms of value.
5.An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
6.Key market players within the nanomedicine market are profiled in this report and their strategies are analyzed thoroughly, which help in understanding competitive outlook of the market.

Scope of Nanomedicine Market Report

Report Metric	Details
Report Name	Nanomedicine Market
Segment by MODALITY	Diagnostics Treatment
Segment by INDICATION	Clinical Oncology Infectious Diseases Clinical Cardiology Orthopedics Neurology Urology Ophthalmology Immunology Others
Segment by Application	Drug Delivery Diagnostic Imaging Vaccines Regenerative Medicine Implants Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Abbott Laboratories DiaSorin S.p.A. General Electric Company Invitae Corporation Johnson & Johnson Leadient BioSciences Inc. Mallinckrodt plc Merck & Co., Inc. Pfizer Inc. Teva Pharmaceuticals Ltd.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter 1 : INTRODUCTION

1:INTRODUCTION

1.1.Report Description

1.2.Key Market Segments

1.3.Key Benefits

1.4.Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

Chapter 2 : EXECUTIVE SUMMARY

2:EXECUTIVE SUMMARY

2.1.CXO Perspective

Chapter 3 : MARKET LANDSCAPE

3:MARKET LANDSCAPE

3.1.Market Definition and Scope

3.2.Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3.Porter's Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.4.Market Share Analysis/Top Player Positioning

3.4.1. Market Share Analysis/Top Player Positioning 2020

3.5.Market Dynamics

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities

3.6.COVID-19 Impact Analysis

Chapter 4 : NANOMEDICINE MARKET, BY APPLICATION

4:NANOMEDICINE MARKET, BY APPLICATION

4.1.Market Overview

4.1.1Market Size and Forecast, By Application

4.2. Drug Delivery

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.3. Diagnostic Imaging

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

4.4. Regenerative Medicine

4.4.1. Key Market Trends, Growth Factors and Opportunities

4.4.2. Market Size and Forecast, By Region

4.4.3. Market Share Analysis, By Country

4.5. Implants

4.5.1. Key Market Trends, Growth Factors and Opportunities

4.5.2. Market Size and Forecast, By Region

4.5.3. Market Share Analysis, By Country

4.6. Vaccines

4.6.1. Key Market Trends, Growth Factors and Opportunities

4.6.2. Market Size and Forecast, By Region

4.6.3. Market Share Analysis, By Country

4.7. Others

4.7.1. Key Market Trends, Growth Factors and Opportunities

4.7.2. Market Size and Forecast, By Region

4.7.3. Market Share Analysis, By Country

Chapter 5 : NANOMEDICINE MARKET, BY INDICATION

5:NANOMEDICINE MARKET, BY INDICATION

5.1.Market Overview

5.1.1Market Size and Forecast, By Indication

5.2. Clinical Oncology

5.2.1. Market Size and Forecast, By Region

5.2.2. Market Share Analysis, By Country

5.3. Infectious Diseases

5.3.1. Market Size and Forecast, By Region

5.3.2. Market Share Analysis, By Country

5.4. Clinical Cardiology

5.4.1. Market Size and Forecast, By Region

5.4.2. Market Share Analysis, By Country

5.5. Orthopedics

5.5.1. Market Size and Forecast, By Region

5.5.2. Market Share Analysis, By Country

5.6. Neurology

5.6.1. Market Size and Forecast, By Region

5.6.2. Market Share Analysis, By Country

5.7. Urology

5.7.1. Market Size and Forecast, By Region

5.7.2. Market Share Analysis, By Country

5.8. Ophthalmology

5.8.1. Market Size and Forecast, By Region

5.8.2. Market Share Analysis, By Country

5.9. Immunology

5.9.1. Market Size and Forecast, By Region

5.9.2. Market Share Analysis, By Country

5.10. Others

5.10.1. Market Size and Forecast, By Region

5.10.2. Market Share Analysis, By Country

Chapter 6 : NANOMEDICINE MARKET, BY MODALITY

6:NANOMEDICINE MARKET, BY MODALITY

6.1.Market Overview

6.1.1.Market Size and Forecast, By Modality

6.2. Treatments

6.2.1. Market Size and Forecast, By Region

6.2.2. Market Share Analysis, By Country

6.3. Diagnostics

6.3.1. Market Size and Forecast, By Region

6.3.2. Market Share Analysis, By Country

Chapter 7 : NANOMEDICINE MARKET, BY REGION

Chapter 8 : COMPANY PROFILES

LIST OF TABLES

TABLE 1.GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 2.GLOBAL NANOMEDICINE MARKET FOR DRUG DELIVERY, BY REGION, 2020-2030 ($MILLION)

TABLE 3.GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTIC IMAGING, BY REGION, 2020-2030 ($MILLION)

TABLE 4.GLOBAL NANOMEDICINE MARKET FOR REGENERATIVE MEDICINE, BY REGION, 2020-2030 ($MILLION)

TABLE 5.GLOBAL NANOMEDICINE MARKET FOR IMPLANTS, BY REGION, 2020-2030 ($MILLION)

TABLE 6.GLOBAL NANOMEDICINE MARKET FOR VACCINES, BY REGION, 2020-2030 ($MILLION)

TABLE 7.GLOBAL NANOMEDICINE MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)

TABLE 8.GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2020-2030 ($MILLION)

TABLE 9.GLOBAL NANOMEDICINE MARKET FOR CLINICAL ONCOLOGY, BY REGION, 2020-2030 ($MILLION)

TABLE 10.GLOBAL NANOMEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2030 ($MILLION)

TABLE 11.GLOBAL NANOMEDICINE MARKET FOR CLINICAL CARDIOLOGY, BY REGION, 2020-2030 ($MILLION)

TABLE 12.GLOBAL NANOMEDICINE MARKET FOR ORTHOPEDICS, BY REGION, 2020-2030 ($MILLION)

TABLE 13.GLOBAL NANOMEDICINE MARKET FOR NEUROLOGY, BY REGION, 2020-2030 ($MILLION)

TABLE 14.GLOBAL NANOMEDICINE MARKET FOR UROLOGY, BY REGION, 2020-2030 ($MILLION)

TABLE 15.GLOBAL NANOMEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2020-2030 ($MILLION)

TABLE 16.GLOBAL NANOMEDICINE MARKET FOR IMMUNOLOGY, BY REGION, 2020-2030 ($MILLION)

TABLE 17.GLOBAL NANOMEDICINE MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)

TABLE 18.GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2020-2030 ($MILLION)

TABLE 19.GLOBAL NANOMEDICINE MARKET FOR TREATMENTS, BY REGION, 2020-2030 ($MILLION)

TABLE 20.GLOBAL NANOMEDICINE MARKET FOR DIAGNOSTICS, BY REGION, 2020-2030 ($MILLION)

TABLE 21.GLOBAL NANOMEDICINE MARKET, BY REGION, 2020-2030 ($MILLION)

TABLE 22.NORTH AMERICA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 23.NORTH AMERICA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 24.NORTH AMERICA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 25.UNITED STATES NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 26.UNITED STATES NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 27.UNITED STATES NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 28.CANADA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 29.CANADA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 30.CANADA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 31.MEXICO NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 32.MEXICO NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 33.MEXICO NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 34.EUROPE NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 35.EUROPE NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 36.EUROPE NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 37.GERMANY NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 38.GERMANY NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 39.GERMANY NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 40.FRANCE NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 41.FRANCE NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 42.FRANCE NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 43.UK NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 44.UK NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 45.UK NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 46.ITALY NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 47.ITALY NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 48.ITALY NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 49.SPAIN NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 50.SPAIN NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 51.SPAIN NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 52.REST OF EUROPE NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 53.REST OF EUROPE NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 54.REST OF EUROPE NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 55.ASIA-PACIFIC NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 56.ASIA-PACIFIC NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 57.ASIA-PACIFIC NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 58.JAPAN NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 59.JAPAN NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 60.JAPAN NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 61.CHINA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 62.CHINA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 63.CHINA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 64.AUSTRALIA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 65.AUSTRALIA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 66.AUSTRALIA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 67.INDIA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 68.INDIA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 69.INDIA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 70.SOUTH KOREA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 71.SOUTH KOREA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 72.SOUTH KOREA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 73.REST OF ASIA-PACIFIC NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 74.REST OF ASIA-PACIFIC NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 75.REST OF ASIA-PACIFIC NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 76.LAMEA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 77.LAMEA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 78.LAMEA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 79.BRAZIL NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 80.BRAZIL NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 81.BRAZIL NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 82.SAUDI ARABIA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 83.SAUDI ARABIA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 84.SAUDI ARABIA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 85.SOUTH AFRICA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 86.SOUTH AFRICA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 87.SOUTH AFRICA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 88.REST OF LAMEA NANOMEDICINE, BY APPLICATION, 2020-2030 ($MILLION)

TABLE 89.REST OF LAMEA NANOMEDICINE, BY INDICATION, 2020-2030 ($MILLION)

TABLE 90.REST OF LAMEA NANOMEDICINE, BY MODALITY, 2020-2030 ($MILLION)

TABLE 91.ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 92.ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 93.ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 94.ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 95.ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 96.DIASORIN S.P.A.: KEY EXECUTIVES

TABLE 97.DIASORIN S.P.A.: COMPANY SNAPSHOT

TABLE 98.DIASORIN S.P.A.: OPERATING SEGMENTS

TABLE 99.DIASORIN S.P.A.: PRODUCT PORTFOLIO

TABLE 100.DIASORIN S.P.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 101.GENERAL ELECTRIC COMPANY: KEY EXECUTIVES

TABLE 102.GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT

TABLE 103.GENERAL ELECTRIC COMPANY: OPERATING SEGMENTS

TABLE 104.GENERAL ELECTRIC COMPANY: PRODUCT PORTFOLIO

TABLE 105.GENERAL ELECTRIC COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 106.INVITAE CORPORATION: KEY EXECUTIVES

TABLE 107.INVITAE CORPORATION: COMPANY SNAPSHOT

TABLE 108.INVITAE CORPORATION: OPERATING SEGMENTS

TABLE 109.INVITAE CORPORATION: PRODUCT PORTFOLIO

TABLE 110.INVITAE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 111.JOHNSON & JOHNSON: KEY EXECUTIVES

TABLE 112.JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 113.JOHNSON & JOHNSON: OPERATING SEGMENTS

TABLE 114.JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 115.JOHNSON & JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 116.LEADIANT BIOSCIENCES, INC.: KEY EXECUTIVES

TABLE 117.LEADIANT BIOSCIENCES, INC.: COMPANY SNAPSHOT

TABLE 118.LEADIANT BIOSCIENCES, INC.: OPERATING SEGMENTS

TABLE 119.LEADIANT BIOSCIENCES, INC.: PRODUCT PORTFOLIO

TABLE 120.LEADIANT BIOSCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 121.MALLINCKRODT PLC: KEY EXECUTIVES

TABLE 122.MALLINCKRODT PLC: COMPANY SNAPSHOT

TABLE 123.MALLINCKRODT PLC: OPERATING SEGMENTS

TABLE 124.MALLINCKRODT PLC: PRODUCT PORTFOLIO

TABLE 125.MALLINCKRODT PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 126.MERCK & CO., INC.: KEY EXECUTIVES

TABLE 127.MERCK & CO., INC.: COMPANY SNAPSHOT

TABLE 128.MERCK & CO., INC.: OPERATING SEGMENTS

TABLE 129.MERCK & CO., INC.: PRODUCT PORTFOLIO

TABLE 130.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 131.PFIZER, INC.: KEY EXECUTIVES

TABLE 132.PFIZER, INC.: COMPANY SNAPSHOT

TABLE 133.PFIZER, INC.: OPERATING SEGMENTS

TABLE 134.PFIZER, INC.: PRODUCT PORTFOLIO

TABLE 135.PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 136.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES

TABLE 137.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 138.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS

TABLE 139.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 140.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 1.GLOBAL NANOMEDICINE MARKET SEGMENTATION

FIGURE 2.GLOBAL NANOMEDICINE MARKET

FIGURE 3.SEGMENTATION NANOMEDICINE MARKET

FIGURE 4.TOP INVESTMENT POCKET IN NANOMEDICINE MARKET

FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*

FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)

FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*

FIGURE 8.MODERATE BARGAINING POWER OF BUYERS

FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 10.MODERATE THREAT OF NEW ENTRANTS

FIGURE 11.LOW THREAT OF SUBSTITUTION

FIGURE 12.HIGH COMPETITIVE RIVALRY

FIGURE 13.TOP PLAYER POSITIONING, 2020

FIGURE 14.MARKET SHARE ANALYSIS, 2020

FIGURE 15.RESTRAINTS AND DRIVERS: NANOMEDICINE MARKET

FIGURE 16.NANOMEDICINE MARKET SEGMENTATION, BY APPLICATION

FIGURE 17.NANOMEDICINE MARKET FOR DRUG DELIVERY, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 18.NANOMEDICINE MARKET FOR DIAGNOSTIC IMAGING, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 19.NANOMEDICINE MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 20.NANOMEDICINE MARKET FOR IMPLANTS, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 21.NANOMEDICINE MARKET FOR VACCINES, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 22.NANOMEDICINE MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 23.NANOMEDICINE MARKET SEGMENTATION, BY INDICATION

FIGURE 24.NANOMEDICINE MARKET FOR CLINICAL ONCOLOGY, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 25.NANOMEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 26.NANOMEDICINE MARKET FOR CLINICAL CARDIOLOGY, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 27.NANOMEDICINE MARKET FOR ORTHOPEDICS, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 28.NANOMEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 29.NANOMEDICINE MARKET FOR UROLOGY, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 30.NANOMEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 31.NANOMEDICINE MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 32.NANOMEDICINE MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 33.NANOMEDICINE MARKET SEGMENTATION, BY MODALITY

FIGURE 34.NANOMEDICINE MARKET FOR TREATMENTS, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 35.NANOMEDICINE MARKET FOR DIAGNOSTICS, BY COUNTRY, 2020-2030 ($MILLION)

FIGURE 36.ABBOTT LABORATORIES: NET SALES, 2018-2020 ($MILLION)

FIGURE 37.ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2020 (%)

FIGURE 38.ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2020 (%)

FIGURE 39.DIASORIN S.P.A.: NET SALES, 2018-2020 ($MILLION)

FIGURE 40.DIASORIN S.P.A.: REVENUE SHARE, BY SEGMENT, 2020 (%)

FIGURE 41.DIASORIN S.P.A.: REVENUE SHARE, BY REGION, 2020 (%)

FIGURE 42.GENERAL ELECTRIC COMPANY: NET SALES, 2018-2020 ($MILLION)

FIGURE 43.GENERAL ELECTRIC COMPANY: REVENUE SHARE, BY SEGMENT, 2020 (%)

FIGURE 44.GENERAL ELECTRIC COMPANY: REVENUE SHARE, BY REGION, 2020 (%)

FIGURE 45.INVITAE CORPORATION: NET SALES, 2018-2020 ($MILLION)

FIGURE 46.INVITAE CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)

FIGURE 47.INVITAE CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)

FIGURE 48.JOHNSON & JOHNSON: NET SALES, 2018-2020 ($MILLION)

FIGURE 49.JOHNSON & JOHNSON: REVENUE SHARE, BY SEGMENT, 2020 (%)

FIGURE 50.JOHNSON & JOHNSON: REVENUE SHARE, BY REGION, 2020 (%)

FIGURE 51.LEADIANT BIOSCIENCES, INC.: NET SALES, 2018-2020 ($MILLION)

FIGURE 52.LEADIANT BIOSCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)

FIGURE 53.LEADIANT BIOSCIENCES, INC.: REVENUE SHARE, BY REGION, 2020 (%)

FIGURE 54.MALLINCKRODT PLC: NET SALES, 2018-2020 ($MILLION)

FIGURE 55.MALLINCKRODT PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)

FIGURE 56.MALLINCKRODT PLC: REVENUE SHARE, BY REGION, 2020 (%)

FIGURE 57.MERCK & CO., INC.: NET SALES, 2018-2020 ($MILLION)

FIGURE 58.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)

FIGURE 59.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2020 (%)

FIGURE 60.PFIZER, INC.: NET SALES, 2018-2020 ($MILLION)

FIGURE 61.PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)

FIGURE 62.PFIZER, INC.: REVENUE SHARE, BY REGION, 2020 (%)

FIGURE 63.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, 2018-2020 ($MILLION)

FIGURE 64.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)

FIGURE 65.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY REGION, 2020 (%)

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$5769

This license allows only one user to access the PDF.

Enterprise User

Electronic (PDF)

$10663

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Nanomedicine Market Size, Share, Competitive Landscape and Trend Analysis Report, by Modality, Application and Indication : Global Opportunity Analysis and Industry Forecast, 2021-2030

Published Date: November 2019

Report Code: ALLI-Auto-4R191

Nanomedicine Market Size, Share, Competitive Landscape and Trend Analysis Report, by Modality, Application and Indication : Global Opportunity Analysis and Industry Forecast, 2021-2030

Scope of Nanomedicine Market Report